Skip to content

uniQure QURE Additional Paid-In Capital

Additional Paid-In Capital at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$4.48B+5.4%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$3.1B+11.3%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.78B+6.5%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$3.88B+16.8%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$1.2B+6.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$2.11B+9.0%

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's additional paid-in capital?
uniQure (QURE) reported additional paid-in capital of $1.59B in Q1 2026.
How has uniQure's additional paid-in capital changed year-over-year?
uniQure's additional paid-in capital increased by 26.2% year-over-year, from $1.26B to $1.59B.
What is the long-term trend for uniQure's additional paid-in capital?
Over 5 years (2020 to 2025), uniQure's additional paid-in capital has grown at a 9.3% compound annual growth rate (CAGR), from $1.02B to $1.58B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.